Previous 10 | Next 10 |
2024-03-25 11:05:30 ET More on Landos Biopharma Seeking Alpha’s Quant Rating on Landos Biopharma Historical earnings data for Landos Biopharma Financial information for Landos Biopharma Read the full article on Seeking Alpha For further details...
2024-03-25 10:00:59 ET More on Health Care Select Sector SPDR XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run Johnson & Johnson, Boston Scientific least shorted stocks in S&...
A look at the top 10 most actives in the United States Next.e.GO N.V. (EGOX) rose 90.8% to $0.075 on volume of 125,000,352 shares Fisker Inc. Class A (FSR) fell 28.2% to $0.08965 on volume of 60,620,440 shares Lucid Group Inc. (LCID) rose 17.3% to $3.2489 on volume of 33,193,462 shares ...
AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases PR Newswire Landos' lead asset, NX-13, is a first-in-class, oral NLRX1 agonist in Phase 2 for the treatment of ulcerative colitis (UC) NORTH CHICAGO, Ill...
2024-03-21 10:34:38 ET More on Landos Biopharma Seeking Alpha’s Quant Rating on Landos Biopharma Historical earnings data for Landos Biopharma Financial information for Landos Biopharma Read the full article on Seeking Alpha For further details...
Top-line Results from the NEXUS Phase 2 Clinical Trial of NX-13 for Ulcerative Colitis Planned for Q4 2024 Sufficient Cash to Fund Planned Operations into mid-2025 NEW YORK, March 21, 2024 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP) (“Landos” or ...
2024-03-18 02:16:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-03-08 03:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-02-26 18:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NEW YORK, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP) (“Landos” or the “Company”), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced that six abstracts were acc...
News, Short Squeeze, Breakout and More Instantly...
Landos Biopharma Inc. Company Name:
LABP Stock Symbol:
NASDAQ Market:
Landos Biopharma Inc. Website:
2024-05-26 06:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
AbbVie Completes Acquisition of Landos Biopharma PR Newswire - Adds first-in-class investigational asset, NX-13, to AbbVie's pipeline with the potential to offer a novel approach to the treatment of ulcerative colitis (UC) and Crohn's disease (CD) NORTH CHICAGO, Ill....
2024-05-06 13:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...